Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy

[1]  M. Gnant,et al.  Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[3]  E. Lewiecki,et al.  Osteoporosis , 2011, Annals of Internal Medicine.

[4]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[5]  M. Beckmann,et al.  Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. , 2009, The Lancet. Oncology.

[6]  S. Cummings.  The Effects of Tibolone in Older Postmenopausal Women , 2008 .

[7]  M. Aickin,et al.  Hip bone density predicts breast cancer risk independently of Gail score , 2008, Cancer.

[8]  S. Cummings,et al.  The effects of tibolone in older postmenopausal women. , 2008, The New England journal of medicine.

[9]  Kari Stefansson,et al.  Multiple genetic loci for bone mineral density and fractures. , 2008, The New England journal of medicine.

[10]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Neven,et al.  Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.

[12]  J. Cauley,et al.  Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis , 2008, Current medical research and opinion.

[13]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[14]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[15]  J. Bilezikian,et al.  A referent bone mineral density database for Chinese American women , 2006, Osteoporosis International.

[16]  P. Kenemans,et al.  Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. , 2005, Maturitas.

[17]  A. M. López,et al.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[18]  J. Cuzick,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[19]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[20]  S. Cummings,et al.  Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Cummings,et al.  Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. , 1996, JAMA.

[22]  S. Cummings,et al.  Bone Mineral Density and Risk of Breast Cancer in Older Women: The Study of Osteoporotic Fractures , 1996 .

[23]  Jack Wang,et al.  Bone mineral density and mass in a cross‐sectional study of white and asian women , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  A. Howell,et al.  Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.

[25]  H. Genant,et al.  Spinal trabecular bone loss and fracture in American and Japanese women , 2006, Osteoporosis International.